Trial Profile
Natalizumab Temporary Discontinuation Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms NaTDS
- 24 May 2016 New trial record